Q5114 Trastuzumab-dkst - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Trastuzumab-dkst

Brand Name:

Ogivri

Strength:

10mg

HCPCS:

Q5114

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

HER2

Oral (Y/N):

No

FDA Approval Year:

2017

FDA Discontinuation Year:

CMS Effective Date:

July 1, 2019

CMS Discontinuation Date:

Status:

In Use